Product details
Background：IL-23Aencodes the p19 subunit of Interleukin-23, a cytokine that plays an importantrole in the immune response and is secreted by dendritic cells, macrophages andother Antigen-presenting cell. Risankizumab (Skyrizi) is a humanized monoclonalantibody that works by targeting the p19 subunit of Interleukin-23(Il-23) .RISANKIZUMAB specifically binds to the p19 subunit of Il-23 and blocks theinteraction between IL-23 and its receptor, thereby inhibiting Th17 celldifferentiation and the release of proinflammatory factors such as Il-17 andIl-22. Risankizumab alleviates pathological damage by inhibiting the IL-23/Th17inflammatory axis, reducing inflammatory cell infiltration and cytokine stormin tissues such as the skin, intestine, and so on.
